Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccine development for potential bioterrorism agents.

R W Titball1, E D Williamson

  • 1Defence Science and Technology Laboratory, Porton Down, Salisbury, UK. RTITBALL@DSTL.GOV.UK

Current Drug Targets. Infectious Disorders
|October 8, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of CD200R Activation in Combination with Doxycycline in a Model of Melioidosis.

Microbiology spectrum·2023
Same author

Role of RelA and SpoT in Burkholderia pseudomallei survival, biofilm formation and ceftazidime tolerance during nutritional stress.

Tropical biomedicine·2021
Same author

Vaccines for emerging pathogens: from research to the clinic. Part two.

Clinical and experimental immunology·2019
Same author

Antibody-mediated protection against MERS-CoV in the murine model.

Vaccine·2019
Same author

Burkholderia thailandensis strain E555 is a surrogate for the investigation of Burkholderia pseudomallei replication and survival in macrophages.

BMC microbiology·2019
Same author

CD200R deletion promotes a neutrophil niche for Francisella tularensis and increases infectious burden and mortality.

Nature communications·2019
Same journal

Discoveries of Tat-TAR interaction inhibitors for HIV-1.

Current drug targets. Infectious disorders·2006
Same journal

Chemosensitizers in drug transport mechanisms involved in protozoan resistance.

Current drug targets. Infectious disorders·2006
Same journal

Neuraminidase inhibitors as antiviral agents.

Current drug targets. Infectious disorders·2006
Same journal

Developments in antiviral drug design, discovery and development in 2004.

Current drug targets. Infectious disorders·2006
Same journal

Identification of inhibitors of bacterial enoyl-acyl carrier protein reductase.

Current drug targets. Infectious disorders·2005
Same journal

The molecular basis for the mode of action of bicyclomycin.

Current drug targets. Infectious disorders·2005
See all related articles

Developing new vaccines against bioterrorism agents is crucial. Research focuses on using genome sequences to identify antigens and non-invasive delivery methods for rapid protection.

Area of Science:

  • Biodefense
  • Vaccinology
  • Microbial Pathogenesis

Background:

  • Bioterrorism agents pose significant public health threats, necessitating effective countermeasures.
  • Existing vaccines often fail to meet requirements for rapid, non-invasive protection against diverse routes of infection.
  • Limited research and high containment needs for many bioterrorism pathogens hinder vaccine development.

Purpose of the Study:

  • To review prospects for a new generation of vaccines against bioterrorism agents.
  • To highlight the importance of utilizing genomic information and advanced formulation technologies.

Main Methods:

  • Leveraging completed or near-completed genome sequences of bioterrorism agents to identify potential vaccine antigens.
  • Developing methodologies for rapid antigen discovery directly from genomic data.

Related Experiment Videos

  • Focusing on vaccine formulations for rapid induction of immunity via non-invasive delivery.

    • Main Results:

    • Genome sequencing provides a powerful tool for identifying novel vaccine targets.
    • Advances in formulation science are enabling non-invasive vaccine delivery and rapid immune response.
    • The combination of genomic data and advanced formulation offers a promising path for next-generation bioterrorism vaccines.

    Conclusions:

    • Exploiting genomic information is key to developing improved vaccines against bioterrorism agents.
    • Non-invasive delivery and rapid induction of immunity are critical requirements for effective bioterrorism vaccines.
    • A new generation of bioterrorism vaccines is feasible by integrating genomic approaches and advanced formulation technologies.